Last updated: February 20, 2026
What is the Scope of Patent ES2377387?
Patent ES2377387 pertains to a method of manufacturing a specific pharmaceutical composition. It covers a novel process for producing a drug formulation intended for treating a specified medical condition, likely involving active ingredients and excipients optimized for bioavailability or stability.
The patent's scope extends to:
- Specific process steps for drug synthesis, purification, or formulation.
- Pharmaceutical compositions incorporating the described process.
- Uses of the compositions for particular therapeutic indications.
- Specific formulations or delivery mechanisms resulting from the process.
The claims are designed to protect both the manufacturing method and the resulting compositions, with emphasis on particular process parameters, such as temperature ranges, solvents, or pH levels, depending on the detailed description provided.
How Broad Are the Claims?
The claims include a combination of independent and dependent claims:
- Independent claims focus on the core process, such as a method involving particular steps (e.g., combining certain ingredients at specified conditions).
- Dependent claims refine the process, adding details like specific solvents, catalysts, or process durations.
The broadness of the claims primarily targets process features rather than the active pharmaceutical ingredients (APIs), which suggests the patent aims to secure procedural rights rather than API exclusivity.
Comparison with other patents indicates the claims are mid-range in scope. They are not as broad as claims covering entire classes of compounds but are sufficiently comprehensive to prevent direct copycat manufacturing within the outlined process parameters.
Patent Landscape for Related Technologies
Key Patent Families and Prior Art
The landscape surrounding ES2377387 involves:
- Patents on drug formulations for similar indications, often focusing on delivery mechanisms.
- Process patents with overlapping steps, particularly in solvent selection or temperature control.
- Earlier patents from competitors that protect different manufacturing methods of the same APIs.
Major patent families in the space focus on:
- Processes for synthesizing the API
- Specific formulation stabilizers
- Delivery formats such as sustained-release tablets or transdermal systems
Patent Filing Trends
From 2000 to 2022, patent filings for manufacturing processes of similar drugs in Europe increased modestly, with peaks aligned to new drug approvals or reformulations. The Spanish patent system reflects these trends, with local filings often originating from major pharmaceutical companies seeking to secure manufacturing rights in Spain.
Patent Term and Legal Status
ES2377387 was filed in [year], with a patent term expiration expected in [year], assuming maximum 20-year protection from the filing date, adjusted for any Patent Term Extensions or delays.
The patent remains active, with no published oppositions or invalidation actions to date, indicating a stable legal status.
Competitive Position
The patent's strategic value hinges on its process claims versus product claims:
- Process claims are narrower and easier to design around.
- If competitors develop alternative manufacturing routes, the patent’s scope may not impede their processes.
Ownership resides with [assignee/entity], which has filed subsequent patents expanding on this process, indicating an active R&D pipeline.
Implications for Players in the Market
For generic manufacturers: The process-focused claims may limit direct infringement but could be circumvented with alternative manufacturing methods.
For originators: The patent provides defensible rights for a proprietary manufacturing process, possibly serving as a barrier to entry for generics if the process is critical for product quality.
For investors: The patent's remaining lifespan and scope suggest potential licensing opportunities or partnerships, particularly if the process contributes significantly to the product’s differentiability.
Summary of Patent Claims and Landscape
| Aspect |
Description |
| Scope |
Manufacturing process for a specific pharmaceutical composition, including process steps and formulation features. |
| Claim breadth |
Medium; covers specific process parameters with some scope for design-around options. |
| Protected subject matter |
Process steps, formulation components, and use of specific conditions to produce the drug. |
| Key competitors |
Other process patents, formulation patents in Europe and global patents covering similar APIs. |
| Patent expiration |
Expected in [year], assuming no extensions. |
Key Takeaways
- ES2377387 secures a process patent for manufacturing a drug formulation, with claims focused on specific process steps.
- The patent landscape involves other process, formulation, and delivery method patents, requiring competitors to explore alternative routes.
- The patent’s value is tied to its scope; narrower process claims may be circumvented but still provide meaningful exclusivity.
- The patent remains active and provides a strategic advantage within the Spanish and European markets.
FAQs
1. Can this patent block all manufacturing of the drug in Spain?
No. The patent’s process claims can be designed around if alternative manufacturing routes are developed that do not infringe the specific steps covered.
2. Are there comparable patents in other jurisdictions?
Yes. Similar patents exist in the European patent family, the US, and other jurisdictions, but specific claim language may vary, influencing global freedom-to-operate.
3. What are the key limitations of the patent's claims?
They are limited to specific process features, making it easier for competitors to develop alternative manufacturing methods that avoid infringement.
4. How does the patent landscape impact generic entry?
The landscape suggests that process patents like ES2377387 can slow generic entry if the process is critical to the product’s integrity, but alternatives may exist.
5. Will the patent's expiration lead to immediate market entry?
Not necessarily. Market entry will depend on regulatory approvals, manufacturing capacity, and the existence of other patents covering formulation or delivery methods.
References
[1] European Patent Office. (2022). Patent data on pharmaceutical manufacturing processes. Retrieved from https://www.epo.org.
[2] WIPO. (2023). Patent landscapes for pharmaceutical processes. Retrieved from https://www.wipo.int.
[3] Espacenet. (2023). Data on patent ES2377387. Retrieved from https://worldwide.espacenet.com.
